2026年，AI制药行业正面临前所未有的转型。在这场从颠覆者到服务商的集体转身中，许多曾经的行业明星，如VergeGenomics和Recursion，正在重新定义新药研发的底层逻辑。曾几何时，这些企业以颠覆传统新药研发为目标，奔赴千亿市场，然而，随着临床接连的失败和资本市场的理性回归，行业的热潮逐渐消退，企业们不得不放下淘金铲，转向更稳妥的“卖水”模式。 临床失败的阴影笼罩着AI制药的未来。两年 ...

Recursion Pharmaceuticals ...

2026年3月25日， Recursion（RXRX）披露1笔公司内部人交易情况。董事Gibson Christopher于2026年3月23日卖出4.00万股。【近期内部交易】披露日期职位姓名交易日期买/卖数量每股成交价/美元总金额/美元 ...

Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: ...

NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with ...

纽约和盐湖城 - Citeline于周二宣布扩大与 Recursion (纳斯达克股票代码:RXRX) 的合作伙伴关系,将真实世界数据能力整合到这家生物技术公司的药物开发平台中。 此次合作将Citeline的真实世界数据和证据能力添加到Recursion现有平台中,该平台结合了多模态数据集、人工智能模型和实验生物学。根据新闻稿声明,此次整合旨在支持试验设计、站点选择和开发决策。

Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best multibagger penny stocks to invest in. On March 31, Recursion ...

Alphabet may be moving in the wrong direction this year, at least so far, but the company's multiple growth avenues (even ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

In March 2026, Citeline announced an expanded strategic partnership with Recursion Pharmaceuticals to integrate Citeline's real-world data and evidence into Recursion’s tech-enabled drug discovery and ...